Atopic dermatitis: A practice parameter update 2012 - 30/01/13
Abstract |
This parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing “Atopic dermatitis: a practice parameter update 2012.” This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
Published practice parameters of the Joint Task Force on Practice Parameters for Allergy & Immunology are available online at www.jcaai.org.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis/atopic eczema, pathogenesis, genetics, diagnosis, management, therapy, triggers, Staphylococcus, quality of life, sleep, cyclosporine, immunomodulating agents, phototherapy, allergen immunotherapy
Plan
| Disclosure of potential conflict of interest: L. Schneider has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) Atopic Dermatitis Research Network and Astellas, is on the Research Advisory Board for the Food Allergy Initiative, and is on the Scientific Advisory Board for the National Eczema Association. S. Tilles has consultant arrangements with SRXA, Sunovion, and Hyrox; has received grants from Astellas, Amphastar, Medimmune, Genentech, Merck, TEVA, Sunovion, Boehringer Ingelheim, Nutricia, Array, Rigel, and AstraZeneca; is Associate Editor for AllergyWatch and the Annals of Allergy; is Assistant Editor for the Joint Task Force for Practice Parameters; and is on the Executive Committee for the Seattle Food Allergy Consortium. P. Lio is a speaker and consultant for Johnson & Johnson’s Neosporin line, has received grants from the Atopic Dermatitis Foundation, and is an Advisory Board Member for the National Eczema Association. M. Boguniewicz has received grants from the NIH. L. Beck has received remuneration from Regeneron and Genentech and has received grants from the NIH, the NIAID, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases; is a board member for the Society for Investigative Dermatology; and is a Scientific Advisory Board member for the National Eczema Association. J. LeBovidge is a consultant/writer for Anaphylaxis Canada. N. Novak has received grants from the German Research Council and has consultant arrangements with ALK-Abelló, Bencard Allergy Therapeutics, Astellas, GlaxoSmithKline, LETI Pharma, and HAL Allergy. |
|
| Corresponding author: Joint Task Force on Practice Parameters, 59 N Brockway St, #304, Palatine, IL 60067. E-mail: info@jcaai.org. |
Vol 131 - N° 2
P. 295 - février 2013 Retour au numéro
Article précédent
- Classification of primary immunodeficiencies: Need for a revised approach?
- Paraskevi Maggina, Andrew R. Gennery
- Atopic dermatitis results in intrinsic barrier and immune abnormalities: Implications for contact dermatitis
- Julia K. Gittler, James G. Krueger, Emma Guttman-Yassky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?